Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.
Alexandra M MillerLuca SzalontayNancy BouvierKatherine HillHamza AhmadJohnathan RafailovAlex J LeeM Irene Rodriguez-SanchezOnur YildirimArti PatelTejus A BaleJamal K BenhamidaRyma BenayedMaria E ArcilaMaria DonzelliIra J DunkelStephen W GilheeneyYasmin KhakooKim KramerSameer F SaitJeffrey P GreenfieldMark M SouweidaneSofia HaqueAudrey MauguenMichael F BergerIngo K MellinghoffMatthias A KarajannisPublished in: Neuro-oncology (2022)
We identified three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making: (1) diagnosis and/or identification of actionable alterations; (2) monitor response to therapy; and (3) tracking tumor evolution. Our findings support broader implementation of clinical CSF cfDNA testing in this population to improve care.
Keyphrases
- young adults
- cerebrospinal fluid
- healthcare
- end stage renal disease
- decision making
- newly diagnosed
- ejection fraction
- chronic kidney disease
- gene expression
- mesenchymal stem cells
- dna methylation
- peritoneal dialysis
- single molecule
- copy number
- genome wide
- social media
- cell therapy
- patient reported outcomes
- affordable care act